Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent: Sizing Up the Drug-Eluting Stent Market

This article was originally published in Start Up

Executive Summary

Xtent founders set out to figure out how a small company could reasonably compete with the likes of Boston Scientific and J&J, who have built such a huge lead in the short time they've had drug-eluting stents. Xtent has developed a next generation system that is designed to eliminate catheter exchanges entirely. Specifically, Xtent's stent delivery platform enables cardiologists to treat multiple lesions of varying lengths with a single device during a single catheter insertion.

You may also be interested in...



Proving Device Incubation Works: An Interview with The Foundry

A decade ago, incuabators were seen as the best medicine for what then ailed the medical device industry, most notably a complex regulatory pathway and a difficult venture financing climate. Perhaps not surprisingly, as both the regulatory path and venture financing grew easier in the mid 2000s, incubators began to struggle, victims of their own financing problems. More recently, two huge acquisitions, Abbott's purchase of Evalve and Medtronic's of Ardian, suggest that at least one incubator, The Foundry, is proving that incubation works.

ART: Bucking the Trend in Bioabsorbable Stents

Bioabsorbable stents arouse great enthusiasm among both interventionalists and industry executives, because they have one major advantage over current stents, both bare metal and drug-eluting: they obviate the need for a permanent implant when only a temporary scaffolding effect is needed. Many stent companies are hedging their bets, working on stents that incorporate both drug elution and bioabsorbability--but not Paris-based Arterial Remodeling Technologies, which is arguing that natural healing, not drug therapy, is the best approach to therapeutically active stents.

Xtent and the Next DES Boom

Safety concerns and a retrenchment in usage have dimmed the luster of drug-eluting stents, but only slightly. If the market is to turn around and, more importantly, serve the kind of patients who really need these devices, a second-generation drug-eluting stent will be needed, one designed specifically for these new patients. And Xtent believe it has the technology to do just that.

Related Content

Related Companies

UsernamePublicRestriction

Register

AP000837

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel